Of note, the activity of M-miR-142 was enhanced by the PD-1 blocking Ab, and the triple combination of M-miR-142, PD-1 Ab and TKI induced the longest survival compared with any doublet combination or single agent, thereby opening a window for novel therapeutic approaches for BC patents. Here, PDCD1 is linked to breast cancer.